The Miami Entrepreneur

CymaBay’s stock surges as Gilead reaches $4.3 billion deal for liver-drug developer

CymaBay Therapeutics shares jumped 24% early Monday after Gilead Sciences reached a $4.3 billion deal to acquire the liver-drug developer.

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post Alphabet, Amazon likely to follow Meta by introducing first-ever dividends in 2024
Next post Are we teaching our children to be beggars — or entrepreneurs? The pitfalls of youth fundraisers.